Premium
Tardy development of safe medicines for children: a Nordic network offers new platform to reduce this inequity
Author(s) -
Naumburg Estelle,
Rane Anders,
Halvorsen Thomas,
Glosli Heidi,
Henriksen Tine Brink,
Haraldsson Àsgeir,
Kallio Jaana,
Lepola Pirkko
Publication year - 2019
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.14775
Subject(s) - medicine , intensive care medicine , risk analysis (engineering)
Less than thirty percent of all marketed drugs worldwide have a paediatric licensing, and less than fifty percent of all marketed drugs are registered for children; in neonates less than ten percent (1, 2). This is not a fair situation since children should have the same right and access to tested medicines as adults. Even so, we see that off-label drugs are increasingly prescribed to children of all ages. This article is protected by copyright. All rights reserved.